


## Background CDK 4/6 inhibitors

Brand Name	Generic Name	EMA	TLV	Company
Ibrance	Palbociclib	2016	2017	Pfizer
Kisqali	Ribociklib	2017	2018	Novartis
Verzenios	Abemaciclib	2018	2019	Eli Lilly

## Data











## **REGION:**

	BLEKINGE 40–49%	KALMAR LAN 20-29%	VARMLAND 20–29%
-89%	DALARNA 20-29%	KRONOBERG 70-79%	VÄSTERBOTTEN 30-39%
	GOTLAND 50-59%	NORRBOTTEN 0-9%	VÄSTERNORRLAND 40–49%
	GÄVLEBORG 50–59%	SKÅNE 40-49%	VÄSTMANLAND 30-39%
	HALLAND 60-69%	STOCKHOLM 40-49%	VÄSTRA GÖTALAND 50-59%
JÄMTLAND HÄRJEDALEN 20–29%		SÖRMLAND 30-39%	ÖREBRO LÄN 40-49%
JÖNKÖPINGS LÄN 40–49%		UPPSALA 80-89%	ÖSTERGÖTLAND 50-59%

\*) FRÅN SOCIALSTYRELSENS LÄKEMEDELSREGISTER FÖR HELÅRET 2021.

**GEMIGTID.NU** 



## #gemigtid

- 1. Campaignsite with petition
- 2. Press release
- 3. Debate article
- 4. TV media
- 5. Social media
- 6. Influencers
- 7. Politicians
- 8. Letters to our societies



"I am dreaming of being able to see my children graduate.

That is the first step".





"I'm not afraid of death. I'm afraid to miss out of my childrens lives".



"It took about one year from first diagnosis and only a couple of months after we learnt that it was metastatic breast cancer".







